Lenalidomide therapy for metastatic renal cell carcinoma.
about
Mechanism of action of lenalidomide in hematological malignanciesPhase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer.Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer.A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinomaA phase I dose-escalation study of lenalidomide in combination with gemcitabine in patients with advanced pancreatic cancer.Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigmSafety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report.Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018.Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma.Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer.Novel therapies in genitourinary cancer: an update.Renal cell carcinoma: how to hit the targets?Lenalidomide: a synthetic compound with an evolving role in cancer management.Lenalidomide in solid tumors.Immuno-oncology for renal cell carcinoma treatment: future perspectives for combinations and sequences with molecularly targeted agents.Updates on novel therapies for metastatic renal cell carcinoma.Trial Watch: Lenalidomide-based immunochemotherapy.Phase 1 dose-escalation study of anti CTLA-4 antibody ipilimumab and lenalidomide in patients with advanced cancers.
P2860
Q21198872-A220A379-C68C-4BE4-AA7C-DBB2BD4C226AQ33408279-74FF7EA7-5B64-4407-B3E3-217BC159CEB5Q33410022-41850663-7075-4F07-A99E-0BB2816F98F6Q33415842-41A90672-2451-481C-A11B-96931AE00C55Q33421680-4D321E13-A718-4B5E-9623-579FABC727BEQ34636002-54A3EE60-4B47-4416-BFC8-AD52BBABDA07Q34666858-1C8BA226-F5DE-4136-9B97-5A6760B49334Q34666866-A0DDFECB-60D4-41DE-BB95-B64C8C017AAAQ35226178-D569A2F1-ABA9-408B-82AB-5972C1A00C59Q36252792-EBB09C62-67D3-4BB2-8498-5B4BEC50F732Q36856612-56701721-5F0E-4F08-8ADD-35666C4CD0ECQ37711561-0328F5CE-A0BE-4DA3-A29A-CBB032B1B494Q37791617-2DA082BE-D685-4860-B218-D621515AB2DCQ38010055-ECBEF0E8-D7D5-41BE-8342-164A83EFC0FCQ38783324-6346E866-0A2F-4590-B609-970B0B18C963Q42728990-59E6A622-7D23-4146-B89D-2116451212E5Q42737828-A8A86A18-1205-40DC-98AC-0727D80D6FA5Q47315414-C567F5DD-4092-45F4-9F35-AA734992634E
P2860
Lenalidomide therapy for metastatic renal cell carcinoma.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
Lenalidomide therapy for metastatic renal cell carcinoma.
@ast
Lenalidomide therapy for metastatic renal cell carcinoma.
@en
type
label
Lenalidomide therapy for metastatic renal cell carcinoma.
@ast
Lenalidomide therapy for metastatic renal cell carcinoma.
@en
prefLabel
Lenalidomide therapy for metastatic renal cell carcinoma.
@ast
Lenalidomide therapy for metastatic renal cell carcinoma.
@en
P2093
P1476
Lenalidomide therapy for metastatic renal cell carcinoma.
@en
P2093
Joan Hernandez-McClain
Muhammad Khan
Robert J Amato
Somyata Saxena
P304
P356
10.1097/COC.0B013E31815E4505
P577
2008-06-01T00:00:00Z